Erratum: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies (Cancer Chemotherapy and Pharmacology 57, (155-164) DOI: 10.1007/s00280-005-0013-8);Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 2, 2006, Pages 155-164

  Holstein, Sarah A ^a   Knapp, Howard R ^c   Clamon, Gerald H ^a   Murry, Daryl J ^b   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Billings Clinic Red Lodge   (United States)

Author keywords

Cholesterol; Hydroxymethylglutaryl coenzyme A reductase inhibitors; Isoprenoid; Malignancy; Phase I

Indexed keywords

AMINOTRANSFERASE; CREATINE KINASE; MEVINOLIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PLASMA; PRIORITY JOURNAL; TIME; UNSPECIFIED SIDE EFFECT;

EID: 28844495629     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0330-6     Document Type: Erratum

References (60)

1. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223
2. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:838
3. Agarwal B, Halmos B, Feoktistov AS, Protiva P, Ramey WG, Chen M, Pothoulakis C, Lamont JT, Holt PR (2002) Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23:521
4. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J (1980) Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Nat Acad Sci USA 77:3957
5. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83
6. Brown MS, Dana SE, Goldstein JL (1974) Regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 249:789
7. Burke LP, Lewis LD, Perez RP (2003) Ubiquinone does not rescue acute myeloid leukemia cells from growth inhibition by statins. Leukemia 17:267
8. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10
9. Davidson MH, Lukacsko P, Sun JX, Phillips G, Walters E, Sterman A, Niecestro R, Friedhoff L (2002) A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther 24:112
10. Desager JP, Horsmans Y (1996) Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 31:348
11. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93:1308
12. Fang W, Liu L, Hsieh JY, Zhao J, Matuszewski BK, Rogers JD, Dobrinska MR (2002) Robotic inhibition assay for determination of HMG-CoA reductase inhibitors in human plasma. J Clin Lab Anal 16:209
13. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M (1998) Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34:406
14. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G, Jakobisiak M (2002) Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100:111
15. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676
16. Flint OP, Masters BA, Gregg RE, Durham SK (1997) Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145:91
17. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y (1993) Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 193:263
18. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW (1989) Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158:667
19. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker Inc., New York
20. Gibbs RA (2000) Farnesyltransferase inhibitors: novel anticancer mechanisms and new therapeutic applications. Curr Opin Drug Discov Devel 3:585
21. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wojcik C, Dabrowska A, Jakobisiak M, Golab J (2002) Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97:746
22. Holstein SA, Hohl RJ (2001) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25:651
23. Holstein SA, Hohl RJ (2001) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141
24. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, Katoh A (1993) Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13:314
25. Kantola T, Kivisto KT, Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397
26. Kayden HJ, Hatam L, Beratis NG (1976) Regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity and the esterification of cholesterol in human long term lymphoid cell lines. Biochemistry 15:521
27. Khan SG, Saxena R, Bickers DR, Mukhtar H, Agarwal R (1995) Inhibition of ras p21 membrane localization and modulation of protein kinase C isozyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin. Mol Carcinog 12:205
28. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ (1995) Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 57:62
29. Lewis KA, Holstein SA, Hohl RJ (2005) Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res (in press)
30. Lindenthal B, von Bergmann K (2000) Urinary excretion and serum concentration of mevalonic acid during acute intake of alcohol. Metab Clin Exp 49:62
31. Lindenthal B, Simatupang A, Dotti MT, Federico A, Lutjohann D, von Bergmann K (1996) Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J Lipid Res 37:2193
32. Lishner M, Bar-Sef A, Elis A, Fabian I (2001) Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Invest Med 49:319
33. Liu L, Zhang R, Zhao JJ, Rogers JD, Hsieh JY, Fang W, Matuszewski BK, Dobrinska MR (2003) Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. J Pharm Biomed Anal 32:107
34. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265
35. Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H (1999) Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 42:1
36. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL (1988) Preclinical evaluation of lovastatin. Am J Cardiol 62:16J
37. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, Ohno R (2000) Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 14:1444
38. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 76:1748
39. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L (1998) Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76
40. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK (1995) In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131:163
41. Matar P, Rozados VR, Roggero EA, Scharovsky OG (1998) Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 13:387
42. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD, Scharovsky OG (1999) Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17:19
43. McKenney JM (1988) Lovastatin: a new cholesterol-lowering agent. Clin Pharm 7:21
44. Muller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, Koch OM (1998) Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wildtype K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 12:717
45. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR (1997) Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 82:1434
46. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA (1990) Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128
47. Perez-Sala D, Mollinedo F (1994) Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209
48. Prasanna P, Thibault A, Liu L, Samid D (1996) Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 66:710
49. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P (1998) Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157:1616
50. Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs 9:2767
51. Sebti SM, Tkalcevic GT, Jani JP (1991) Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 3:141
52. Sinensky M, Beck LA, Leonard S, Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265:19937
53. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R (1992) Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. Cancer Res 52:4348
54. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R, Fumagalli R (1995) In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 55:597
55. Sora MK, Kruszewski AA, Stoklosa T, Czyzyk J, Lasek W, Malejczyk J, Jakobisiak M (1994) Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin. Arch Immunol Ther Exp (Warsz) 42:269
56. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 27:133
57. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483
58. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355
59. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2001) Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15:1398
60. Ye LY, Firby PS, Moore MJ (2000) Determination of lovastatin in human plasma using reverse-phase high-performance liquid chromatography with UV detection. Ther Drug Monit 22:737